Is There a Role for Dacomitinib, a Second-Generation Irreversible Inhibitor of the Epidermal-Growth Factor Receptor Tyrosine Kinase, in Advanced Non-Small Cell Lung Cancer?

Expert Opinion on Pharmacotherapy - United Kingdom
doi 10.1080/14656566.2020.1746269
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Elderly Patients With Advanced Non-Small Cell Lung Cancer

Current Gerontology and Geriatrics Research
GerontologyGeriatrics
2010English

Overcoming Resistance to First/Second Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and ALK Inhibitors in Oncogene-Addicted Advanced Non-Small Cell Lung Cancer

Therapeutic Advances in Medical Oncology
Oncology
2016English

Early Radiographic Response to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations: A Prospective Study

Biomedical Journal
Medicine
2015English

Genetic Alterations in Epidermal Growth Factor Receptor‑tyrosine Kinase Inhibitor‑na�ve Non‑small Cell Lung Carcinoma

Oncology Letters
Cancer ResearchOncology
2020English

Clinical Studies on Conformal Radiotherapy Combined With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor in Second-Line Treatment of Non-Small Cell Lung Cancer

Tropical Journal of Pharmaceutical Research
PharmacologyPharmaceutical Science
2016English

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non–Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor

JAMA - Journal of the American Medical Association
Medicine
2014English

The Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

2013English

The Role of Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer

Dicle Medical Journal / Dicle Tip Dergisi
2015English

P1.01-36 Thoracic Surgery in Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutant After Tyrosine Kinase Inhibitor Therapy

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy